Co-Diagnostics vs Nexalin Technology
Co-Diagnostics reported revenue of $1 million in fiscal 2025, 2.0 times Nexalin Technology's $0 million in fiscal 2025. Co-Diagnostics' revenue fell 84.1% in its latest year, and Nexalin Technology's grew 78.8%. Co-Diagnostics had an operating margin of -8058.8%, against -2781.7% at Nexalin Technology.
Side by side
| Co-Diagnostics | Nexalin Technology | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $1M | $0M |
| Revenue growth | −84.1% | 78.8% |
| Revenue growth a year, last 5 years | −61.9% | — |
| Gross margin | 64.3% | 79.7% |
| Operating margin | −8,058.8% | −2,781.7% |
| Net margin | −7,533.6% | −2,725.8% |
| Free cash flow | −$30M | — |
| Free cash flow margin | −4,793.2% | — |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 31.6% | 77.9% |
| Last close | $0.16 | $1.39 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | — |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Co-DiagnosticsNexalin Technology
Operating margin
Percent of revenue
Co-DiagnosticsNexalin Technology
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Co-DiagnosticsNexalin Technology
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Co-Diagnostics and Nexalin Technology pages.